ashibio
  • Home
  • Pipeline
  • Patients
  • About
  • News & Publications
  • Contact
Select Page

News

āshibio Reports Promising Preclinical Data for Two First-in-Class Antibodies Targeting Debilitating Bone Disorders at ASBMR Meeting

8 September 2025 | Press Release

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

19 August 2025 | Press Release

āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)

24 June 2025 | Press Release

āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

23 January 2025 | Press Release

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

17 September 2024 | Press Release

« Older Entries

Publications & Posters

Vantictumab, an anti-FZD antibody, Rescues the Osteopetrotic Bone Phenotype in Heterozygous ADO Mice

August 2025 | ASBMR, Seattle

MMP9 deficiency protects against trauma-induced heterotopic ossification

July 2025 | ASBMR, Seattle

Inhibition of MMP9 as a novel treatment strategy for fibrodysplasia ossificans progressiva (FOP): Safety analysis of the anti-MMP9 antibody andecaliximab in development for FOP

September 2024 | ASBMR, Toronto

ANDECAL, A Phase 2/3 study to determine the efficacy of the MMP9-inhibitor Andecaliximab to block new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP): Methodology for Part 1 of the Study

June 2024 | IFOPA DDF, Stockholm

ANDECAL, A Phase 2/3 study to determine the efficacy of the MMP9-inhibitor Andecaliximab to block new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP): Methodology for Part 1 of the Study

June 2024 | ICCBH, Salzburg

« Older Entries

© Copyright 2026 āshibio. All rights reserved. | Located in Burlingame, California, USA | Privacy Policy & Terms and Conditions

  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}